Key Performance
More- Earnings Score: N/A
- Momentum Score: 52
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaà Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.
05/20/2026, 9:50 AM • Benzinga
The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.
04/10/2026, 9:55 AM • Benzinga
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
Avaà Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.
03/18/2026, 10:00 AM • Benzinga
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
The healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.
01/29/2026, 1:31 PM • Benzinga
W.P. Carey (WPC) Q2 AFFO Jumps 9.4%
W.P. Carey, a diversified net lease REIT, reported Q2 2025 earnings with strong revenue growth and AFFO per share, despite experiencing net income decline due to non-cash market adjustments. The company raised full-year guidance and increased quarterly dividend.
07/30/2025, 5:07 PM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.